Healthcare provider profile · identity verified

Ryan C Jones, DO

Family Practice · SOUTH JORDAN, UT · NPI 1043328610

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	429	139
Atorvastatin Calcium	Atorvastatin Calcium	405	122
Levothyroxine Sodium	Levothyroxine Sodium	353	99
Omeprazole	Omeprazole	221	72
Lisinopril	Lisinopril	207	68
Amlodipine Besylate	Amlodipine Besylate	178	57
Metformin Hcl	Metformin Hcl	176	57
Tamsulosin Hcl	Tamsulosin Hcl	166	52
Losartan Potassium	Losartan Potassium	161	50
Gabapentin	Gabapentin	149	49
Duloxetine Hcl	Duloxetine Hcl	145	39
Trazodone Hcl	Trazodone Hcl	137	43
Eliquis	Apixaban	135	29
Olmesartan Medoxomil	Olmesartan Medoxomil	130	40
Simvastatin	Simvastatin	130	38
Jardiance	Empagliflozin	112	23
Metformin Hcl Er	Metformin Hcl	112	42
Finasteride	Finasteride	106	31
Fluoxetine Hcl	Fluoxetine Hcl	105	30
Zolpidem Tartrate	Zolpidem Tartrate	103	29
Sertraline Hcl	Sertraline Hcl	91	32
Trulicity	Dulaglutide	89	15
Alendronate Sodium	Alendronate Sodium	88	27
Hydrochlorothiazide	Hydrochlorothiazide	84	29
Metoprolol Succinate	Metoprolol Succinate	84	29
Albuterol Sulfate Hfa	Albuterol Sulfate	73	29
Valsartan	Valsartan	67	20
Tramadol Hcl	Tramadol Hcl	64	13
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	62	12
Celecoxib	Celecoxib	61	26
Allopurinol	Allopurinol	60	13
Famotidine	Famotidine	60	17
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	57	21
Mounjaro	Tirzepatide	52	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	50	20
Escitalopram Oxalate	Escitalopram Oxalate	48	19
Glimepiride	Glimepiride	47	16
Meloxicam	Meloxicam	46	22
Montelukast Sodium	Montelukast Sodium	42	15
Potassium Chloride	Potassium Chloride	42	15
Propranolol Hcl	Propranolol Hcl	42	suppressed
Buspirone Hcl	Buspirone Hcl	41	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	40	11
Venlafaxine Hcl Er	Venlafaxine Hcl	39	11
Pravastatin Sodium	Pravastatin Sodium	38	12
Citalopram Hbr	Citalopram Hydrobromide	37	11
Bupropion Xl	Bupropion Hcl	36	11
Metoprolol Tartrate	Metoprolol Tartrate	36	11
Oxybutynin Chloride Er	Oxybutynin Chloride	34	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	34	suppressed
Alprazolam	Alprazolam	33	14
Fluticasone Propionate	Fluticasone Propionate	33	11
Lansoprazole	Lansoprazole	33	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	33	11
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	31	suppressed
Telmisartan	Telmisartan	31	13
Carvedilol	Carvedilol	29	suppressed
Ezetimibe	Ezetimibe	29	suppressed
Paroxetine Hcl	Paroxetine Hcl	28	suppressed
Spironolactone	Spironolactone	28	suppressed
Furosemide	Furosemide	27	12
Quetiapine Fumarate	Quetiapine Fumarate	27	suppressed
Xarelto	Rivaroxaban	27	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	26	suppressed
Ibuprofen	Ibuprofen	25	13
Farxiga	Dapagliflozin Propanediol	23	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	22	suppressed
Clonazepam	Clonazepam	22	suppressed
Eszopiclone	Eszopiclone	22	suppressed
Warfarin Sodium	Warfarin Sodium	22	suppressed
Ramipril	Ramipril	21	suppressed
Clopidogrel	Clopidogrel Bisulfate	20	suppressed
Azelastine Hcl	Azelastine Hcl	19	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	19	suppressed
Valacyclovir	Valacyclovir Hcl	19	11
Bupropion Hcl Sr	Bupropion Hcl	18	suppressed
Cephalexin	Cephalexin	18	14
Symbicort	Budesonide/Formoterol Fumarate	18	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	17	suppressed
Prednisone	Prednisone	17	12
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	16	suppressed
Ondansetron Odt	Ondansetron	16	suppressed
Propranolol Hcl Er	Propranolol Hcl	16	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	16	13
Baclofen	Baclofen	15	suppressed
Chlorthalidone	Chlorthalidone	15	suppressed
Memantine Hcl	Memantine Hcl	15	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	15	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	suppressed
Synthroid	Levothyroxine Sodium	14	suppressed
Advair Diskus	Fluticasone Propion/Salmeterol	13	suppressed
Estradiol	Estradiol	13	suppressed
Methocarbamol	Methocarbamol	13	suppressed
Nystatin	Nystatin	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	13	suppressed
Bydureon Bcise	Exenatide Microspheres	12	suppressed
Dutasteride	Dutasteride	12	suppressed
Levetiracetam	Levetiracetam	12	suppressed
Lorazepam	Lorazepam	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Terbinafine Hcl	Terbinafine Hcl	12	suppressed
Tizanidine Hcl	Tizanidine Hcl	12	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Amoxicillin	Amoxicillin	11	11
Atenolol	Atenolol	11	suppressed
Fluticasone-Salmeterol Hfa	Fluticasone Propion/Salmeterol	11	suppressed
Humulin N	Insulin Nph Human Isophane	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed
Spiriva Handihaler	Tiotropium Bromide	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error